52.62
Bio Techne Corp (TECH) 最新ニュース
Bio-techne’s technology supports FDA approval of rare skin disorder therapy - Investing.com
Bio-Techne's Simple Western Enables Breakthrough FDA Approval for Rare Skin Disease Gene Therapy - Stock Titan
Bio-Techne stock price target lowered to $75 by Scotiabank - Investing.com South Africa
Minnesota's highest-paid CEOs made 7% more, with highest paid making $59.4M - Star Tribune
Assessing Bio-Techne: Insights From 7 Financial Analysts - Benzinga
Bio-Techne (TECH) Receives Buy Rating with $65 Price Target from TD Cowen | TECH Stock News - GuruFocus
Bio-Techne (TECH): TD Cowen Initiates Coverage with Buy Rating | - GuruFocus
5 Revealing Analyst Questions From Bio-Techne’s Q1 Earnings Call - Yahoo Finance
Is There Now An Opportunity In Bio-Techne Corporation (NASDAQ:TECH)? - Yahoo Finance
How To Trade (TECH) - news.stocktradersdaily.com
Bio-Techne's New USP Deal on mAb and Gene Therapy May Boost Its Stock - Yahoo Finance
Bio-Techne stock holds steady as Stifel maintains $60 price target - Investing.com
Is Bio-Techne Stock Underperforming The Nasdaq? - Barchart.com
Major Breakthrough: Bio-Techne and USP Join Forces to Transform Gene Therapy Development Process - Stock Titan
First Week of August 15th Options Trading For Bio-Techne (TECH) - Nasdaq
Bio-Techne (NASDAQ:TECH) stock performance lags Nasdaq Composite in recent years - Kalkine Media
Bio-Techne Corp. stock underperforms Tuesday when compared to competitors - MarketWatch
How the (TECH) price action is used to our Advantage - news.stocktradersdaily.com
Bio-Techne Director Cashes Out in Significant Stock Sale - TipRanks
Bio-Techne at Goldman Sachs Conference: Strategic Growth Amid Challenges - Investing.com
TECH Q1 Earnings Call: Management Highlights Market Uncertainties and Strategic Mitigation Efforts - Yahoo Finance
Transcript : Bio-Techne Corporation Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-10-2025 10 - MarketScreener
Bio-Techne To Present At Goldman Sachs Global Healthcare Conference; Webcast At 10:40 AM ET - Nasdaq
ScaleReady Announces a G-Rex® Grant has been awarded to Immuneel Therapeutics - Yahoo Finance
Bio-Techne (TECH) Maintains 'Buy' Rating with $75 Price Target | TECH Stock News - GuruFocus
Benchmark maintains Buy rating on Bio-Techne stock amid tariff impact By Investing.com - Investing.com South Africa
Benchmark maintains Buy rating on Bio-Techne stock amid tariff impact - Investing.com India
Stochastic Optical Reconstruction Miicroscope Market Size, - openPR.com
Deutsche Bank Adjusts Bio-Techne Price Target to $66 From $70 - marketscreener.com
Bio-Techne at Jefferies Conference: Strategic Growth Amid Challenges - Investing.com
Transcript : Bio-Techne Corporation Presents at Jefferies Global Healthcare Conference 2025, Jun-04-2025 03 - marketscreener.com
Bio-Techne at William Blair Growth Stock: Strategic Insights and Challenges - Investing.com
Transcript : Bio-Techne Corporation Presents at 45th Annual William Blair Growth Stock Conference, Jun-03-2025 02 - marketscreener.com
Spotting Winners: Bio-Techne (NASDAQ:TECH) And Research Tools & Consumables Stocks In Q1 - Yahoo Finance
Bio-Techne Corp (TECH) Stock Analysis: Unveiling a 43% Potential Upside Amid Challenging Valuations - DirectorsTalk Interviews
Wells Fargo Begins Coverage of Bio-Techne (TECH) Stock, Gives PT of $59 - Insider Monkey
Wells Fargo starts Bio-Techne with Overweight, $59 target - Investing.com Australia
Bio-Techne stock price target cut to $65 by Argus - Investing.com South Africa
Wells Fargo Initiates Coverage on Bio-Techne (TECH) with Overwei - GuruFocus
Wells Fargo starts Bio-Techne with Overweight, $59 target By Investing.com - Investing.com Canada
Demystifying Bio-Techne: Insights From 7 Analyst Reviews - Benzinga
Argus Adjusts Price Target on Bio-Techne to $65 From $90 - marketscreener.com
Wells Fargo Initiates Bio-Techne at Overweight With $59 Price Target - marketscreener.com
Bio-Techne Corporation (TECH): A Bull Case Theory - Insider Monkey
Bio-Techne Corporation: An Insight Into The Pharmaceutical Market Dynamics & China's Economic & Regulatory Environment! - Smartkarma
Is Bio-Techne Stock The Right Pick For Your Portfolio Now? - Barchart.com
Is Bio-Techne Stock the Right Pick for Your Portfolio Now? - Yahoo Finance
Bio-Techne Sets Triple Conference Appearance: William Blair, Jefferies, and Goldman Sachs in June - Stock Titan
Bio-Techne to Present at Investor Conferences - Yahoo Finance
Bio-Techne Corp. stock underperforms Wednesday when compared to competitors - MSN
Cetera Investment Advisers Sells 887 Shares of Bio-Techne Co. (NASDAQ:TECH) - Defense World
Exosomes Market Projected to Reach USD 1,311.03 Million by - GlobeNewswire
大文字化:
|
ボリューム (24 時間):